TY - JOUR
T1 - Protective potential of high-intensity interval training on cardiac structure and function after COVID-19
T2 - protocol and statistical analysis plan for an investigator-blinded randomised controlled trial
AU - Rasmussen, Iben Elmerdahl
AU - Foged, Frederik
AU - Bjørn Budde, Josephine
AU - Rasmussen, Rasmus Syberg
AU - Rasmussen, Villads
AU - Lyngbæk, Mark
AU - Jønck, Simon
AU - Krogh-Madsen, Rikke
AU - Lindegaard, Birgitte
AU - Ried-Larsen, Mathias
AU - Jørgensen, Peter Godsk
AU - Lund, Morten Asp Vonsild
AU - Køber, Lars
AU - Vejlstrup, Niels
AU - Pedersen, Bente Klarlund
AU - Berg, Ronan M G
AU - Christensen, Regitse Højgaard
N1 - © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2021/11/18
Y1 - 2021/11/18
N2 - INTRODUCTION: COVID-19 is associated with a marked systemic inflammatory response with concomitant cardiac injury and remodelling, but it is currently unknown whether the latter is reversible. Given that high-intensity interval training (HIIT) is a powerful stimulus to improve cardiorespiratory fitness while also eliciting marked anti-inflammatory effects, it may be an important countermeasure of reducing cardiopulmonary morbidity following COVID-19.METHODS AND ANALYSIS: 40 COVID-19 survivors who have been discharged from hospital will be included in this investigator-blinded randomised study with a 12-week HIIT intervention. Patients will be 1:1 block-randomised by sex to either a supervised HIIT exercise group or standard care (control group). The main hypothesis is that a 12-week HIIT scheme is a safe way to improve loss of cardiac mass and associated cardiorespiratory fitness, despite hypothesised limited HIIT-induced changes in conventional lung function indices per se. Ultimately, we hypothesise that the HIIT scheme will reduce post-COVID-19 symptoms and improve quality of life.ETHICS AND DISSEMINATION: This study is approved by the Scientific Ethical Committee at the Capital Region of Denmark (H-20033733, including amendments 75068 and 75799) and registered at ClinicalTrials.gov (NCT04647734, pre-results). The findings will be published in a peer-reviewed journal, including cases of positive, negative and inconclusive results.Trial registration number NCT04549337.
AB - INTRODUCTION: COVID-19 is associated with a marked systemic inflammatory response with concomitant cardiac injury and remodelling, but it is currently unknown whether the latter is reversible. Given that high-intensity interval training (HIIT) is a powerful stimulus to improve cardiorespiratory fitness while also eliciting marked anti-inflammatory effects, it may be an important countermeasure of reducing cardiopulmonary morbidity following COVID-19.METHODS AND ANALYSIS: 40 COVID-19 survivors who have been discharged from hospital will be included in this investigator-blinded randomised study with a 12-week HIIT intervention. Patients will be 1:1 block-randomised by sex to either a supervised HIIT exercise group or standard care (control group). The main hypothesis is that a 12-week HIIT scheme is a safe way to improve loss of cardiac mass and associated cardiorespiratory fitness, despite hypothesised limited HIIT-induced changes in conventional lung function indices per se. Ultimately, we hypothesise that the HIIT scheme will reduce post-COVID-19 symptoms and improve quality of life.ETHICS AND DISSEMINATION: This study is approved by the Scientific Ethical Committee at the Capital Region of Denmark (H-20033733, including amendments 75068 and 75799) and registered at ClinicalTrials.gov (NCT04647734, pre-results). The findings will be published in a peer-reviewed journal, including cases of positive, negative and inconclusive results.Trial registration number NCT04549337.
KW - COVID-19
KW - Cardiorespiratory Fitness
KW - High-Intensity Interval Training
KW - Humans
KW - Quality of Life
KW - Randomized Controlled Trials as Topic
KW - SARS-CoV-2
KW - Treatment Outcome
KW - sports medicine
KW - cardiology
UR - http://www.scopus.com/inward/record.url?scp=85120323967&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2020-048281
DO - 10.1136/bmjopen-2020-048281
M3 - Journal article
C2 - 34794987
VL - 11
SP - 1
EP - 10
JO - BMJ Paediatrics Open
JF - BMJ Paediatrics Open
SN - 2044-6055
IS - 11
M1 - e048281
ER -